文献速递流行病学与生物统计临床试验与 GCP

公共卫生随机试验中危害的预设与报告严重不足:一项元流行病学研究

Harms were rarely specified or reported in public health randomized trials: a meta-epidemiological study.
PubMed 文献 · J Clin Epidemiol · 2026-09-23

该元流行病学研究纳入2023年发表的100项公共卫生干预随机对照试验,评估危害的预设、报告及两者一致性。仅25%预设至少一项危害,23%报告任何危害,72%两者均无;有注册或方案者预设与报告危害的比值比更高。

要点

  • 仅25%的公共卫生随机试验预设至少一项危害,23%报告危害。
  • 有注册或研究方案与危害预设及报告几率更高相关。
  • 无试验说明危害报告标准,也无试验按公平性因素分层报告危害。

核心结论

  • 本样本中多数公共卫生随机试验未公开预设或报告危害。
  • 预先设定危害评估方式并完整报告结果有助于公共卫生项目的采纳与调整决策。

研究设计与样本

  • 元流行病学研究,纳入2023年发表、索引于PubMed的100项公共卫生干预随机对照试验的主要全文报告。
  • 利用出版物及公开链接文件(注册、方案、补充材料)评估危害预设、报告、一致性、报告标准透明度及公平性分组。

主要发现

  • 仅25%(25/100)的试验预设至少一项危害,23%(23/100)报告任何危害,72%(72/100)既未预设也未报告危害。
  • 在28项预设或报告危害的试验中,12项(43%)报告了所有预设危害,8项(29%)仅报告部分,8项(29%)存在其他不一致。
  • 有注册列表的试验危害预设比值比为4.7(95%CI:1.5,14.3),有明确方案的试验为3.9(95%CI:1.5,10.1)。
  • 药物干预试验危害预设比值比为9.8(95%CI:1.9,49.9);有注册或方案者危害报告比值比分别为4.0(95%CI:1.3,12.4)和3.8(95%CI:1.4,10.0)。
  • 89%的试验报告在参与者特征中考虑至少一项公平性相关因素,但无试验按这些因素分层报告危害。

关键数值与推荐

  • 无试验预设危害报告标准,也无试验使用可识别标准报告危害。
  • 与平行生物医学样本相比,公共卫生随机试验预设和报告危害的频率远低。

临床怎么用

  • 开展公共卫生随机试验时应预先设定危害评估与报告方式。
  • 应完整报告危害结果,包括按公平性相关因素分层分析。
  • 有注册和方案与更好的危害预设和报告相关,应强化注册与方案中对危害的规划。

局限性

  • 样本仅含100项公共卫生随机试验,危害相关结局稀疏。
  • 亚组发现应视为探索性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterize harms specification, harms reporting, concordance between specified and reported harms, transparency about harms reporting criteria, and equity-related harms considerations in randomized controlled trials (RCTs) of public health interventions. STUDY DESIGN AND SETTING: We conducted a meta-epidemiological study of 100 RCTs of public health interventions whose primary full-text reports were published in 2023 and indexed in PubMed. Using the publication and publicly linked documents (registrations, protocols, and supplements), we assessed harms specification, harms reporting, concordance, transparency of reporting criteria, and whether reported harms were grouped by PROGRESS-Plus equity-related factors. RESULTS: Only 25% (25/100) of trials specified at least one harm, and 23% (23/100) reported any harms, whereas 72% (72/100) neither specified nor reported harms. Among 28 trials that either specified or reported harms, 12 (43%) reported all specified harms, 8 (29%) reported only a subset, and 8 (29%) showed other discordance. No trial specified harms reporting criteria, and none reported harms using identifiable criteria. Trials with a registry listing and those with an identified protocol had higher odds of harms specification compared with trials without a registry or protocol (odds ratio [OR] = 4.7 [95% CI: 1.5, 14.3] and OR = 3.9 [1.5, 10.1], respectively); trials testing pharmacological interventions also showed higher odds of specification compared with other intervention types (OR = 9.8 [1.9, 49.9]). Similarly, harms reporting was higher in trials with a registry or protocol (OR = 4.0 [1.3, 12.4] and OR = 3.8 [1.4, 10.0], respectively). Although 89% of trial reports considered at least one equity-related factor among participant characteristics, none reported harms stratified by these factors. Compared with a parallel biomedical sample, public health RCTs specified and reported harms far less often. CONCLUSION: Most public health RCTs in this sample did not publicly specify or report harms. Prespecifying how harms will be assessed and fully reporting the findings would better support decisions about adopting, modifying, or expanding public health programs. Because the sample included 100 public health RCTs and harms-related outcomes were sparse, subgroup findings should be interpreted as exploratory. PLAIN LANGUAGE SUMMARY: Randomized trials of public health interventions are often used to guide decisions about programs, policies, and preventive strategies. These trials should also help identify possible harms, including unintended or inequitable consequences. We included 100 randomized trials published in 2023 that evaluated public health interventions. Most neither clearly stated which harms they planned to measure nor reported harms results. Trials with a registry listing or study protocol were more likely to specify and report harms, but no trial explained the criteria used to decide which harms were reported and no trial reported harms by equity-related participant characteristics. Clearer planning and reporting would make public health trials more useful when interventions are reviewed, adapted, implemented, or scaled.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Shaughnessy D, Naaman K, Krishan A, et al. Harms were rarely specified or reported in public health randomized trials: a meta-epidemiological study. J Clin Epidemiol. 2026. PMID: 42772606. doi:10.1016/j.jclinepi.2026.112530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。